scispace - formally typeset
D

Daniele Bergamaschi

Researcher at Queen Mary University of London

Publications -  52
Citations -  10414

Daniele Bergamaschi is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Apoptosis & Autophagy. The author has an hindex of 27, co-authored 46 publications receiving 8819 citations. Previous affiliations of Daniele Bergamaschi include Fourth Military Medical University & Mario Negri Institute for Pharmacological Research.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Daniel J. Klionsky, +2983 more
- 08 Feb 2021 - 
TL;DR: In this article, the authors present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes.
Journal ArticleDOI

ASPP proteins specifically stimulate the apoptotic function of p53.

Yardena Samuels-Lev, +9 more
- 26 Oct 2001 - 
TL;DR: The expression of ASPP is frequently downregulated in human breast carcinomas expressing wild-type p53 but not mutant p53, therefore, ASPP regulate the tumor suppression function of p53 in vivo.
Journal ArticleDOI

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Daniele Bergamaschi, +19 more
- 01 Apr 2003 - 
TL;DR: Polymorphism in p53 may influence individual responsiveness to cancer therapy, and clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is influenced by this polymorphism, cancers expressing 72R mutants having lower response rates than those expressing 72P mutants.
Journal ArticleDOI

iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human

Daniele Bergamaschi, +11 more
- 01 Jan 2003 - 
TL;DR: iASPP is an evolutionarily conserved inhibitor of p53; inhibition of iASPP by RNA-mediated interference or antisense RNA in C. elegans or human cells, respectively, induces p53-dependent apoptosis and could provide an important new strategy for treating tumors expressing wild-type p53.